<DOC>
	<DOCNO>NCT01362439</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety paliperidone extend release ( ER ) symptomatic participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) receive treatment oral ( mouth ) antipsychotic medication need switch paliperidone ER current oral antipsychotic therapy due insufficient efficacy due side effect .</brief_summary>
	<brief_title>Paliperidone Extended Release Schizophrenia Participants With Duration Illness Less Than 10 Years</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-centric ( conducted one center ) non-comparative study paliperidone ER participant schizophrenia previous history bad adherence antipsychotic treatment insufficient efficacy side-effects . All eligible participant receive dose paliperidone ER range 3 12 milligram ( mg ) orally ( take mouth ; swallow ) daily 13 week . Efficacy safety primarily evaluate Positive Negative Syndromes Scale ( PANSS ) Extrapyramidal Symptom Rating Scale ( ESRS ) , respectively . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participants meet Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) criterion schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) Positive Negative Syndrome Scale ( PANSS ) total score Baseline great equal 70 less equal 100 Participants need switch current oral antipsychotic therapy lack efficacy side effect Participants follow outpatient Female participant must postmenopausal least 1 year , surgically sterile , sexually active , practice effective method birth control female participant childbearing potential must also negative urine pregnancy test Baseline Acute psychotic relapse require hospitalization first antipsychotic treatment ever Participants receive clozapine previous 3 month History current symptom tardive dyskinesia ( twitch jerk movement control face , tongue , part body ) neuroleptic malignant syndrome ( high fever , rigid muscle , shake , confusion , sweat usual , increased heart rate blood pressure , muscle pain weakness ) Pregnant breastfeed female Participated investigational drug trial previous 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
</DOC>